Immunetune Announces Presentations at Industry Conferences during November 2021
LEIDEN, the Netherlands, November 2, 2021 — Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced the upcoming presentations by members of its management team at several industry and scientific conferences during November 2021.
“We are looking forward to presenting our platform of synthetic DNA vaccines to an audience of investors, pharma and biotech companies, and scientists and investigators,” said Sijme Zeilemaker, CEO of Immunetune. “With our lead program NeoVAC, a personalized neoantigen cancer vaccine, moving towards the clinic in 2022, it is a great opportunity to showcase our unique differentiation and explore collaborations with leaders in this field.”
Upcoming conferences:
Drug Discovery Strategic Summit, November 4 – 5, Amsterdam, the Netherlands
CEO Sijme Zeilemaker will be presenting on November 4th, 9:50 – 10:10 AM, on “Next-generation DNA vaccines targeting cancer and infectious diseases”.
LSX Investival Showcase, November 8 – 15, Virtual / London, UK
CEO Sijme Zeilemaker will be participating virtually and in person on November 15th in London. Please reach out to bd@immunetune.com if you would like to set up a meeting within our scope of investors and pharma/biotech collaborations.
Festival of Biologics / World Immunotherapy Congress, November 9 – 11, Basel, Switzerland
CEO Sijme Zeilemaker will be presenting on November 9th, 5:50 – 6:10 PM, in the Innate & Adaptive Checkpoint Inhibition track on “Neoantigen cancer vaccines based on synthetic linear DNA with a pyroptotic adjuvant synergize with checkpoint inhibitors”.
Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 10 – 14, Virtual / Washington, D.C., US
CSO Jeroen van Bergen will be presenting the poster titled “Personalized synthetic polyepitope DNA cancer vaccines encoding a novel pyroptotic adjuvant to generate effective anti-tumor T cell immunity”. Abstracts can be accessed on the SITC website once the conference begins on November 9th; posters will be presented on November 12 and 13.
About Immunetune
Immunetune is a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases. Its proprietary set of technologies allow the rapid, cell-free production of personalized cancer vaccines encoding multiple (neo-)antigens in synthetic, linear DNA with improved immunogenicity through its unique PyroVant™ adjuvant. Its lead cancer vaccine has achieved preclinical Proof of Concept in animal studies and is finalizing its preclinical package with the aim to initiate clinical studies in 2022. Immunetune’s pipeline further consists of infectious disease vaccines, including a pan-corona DNA vaccine, targeting antigens conserved across multiple strains of coronaviruses for global pandemic readiness, currently in preclinical testing.
For more information, please contact:
Sijme Zeilemaker
Chief Executive Officer
Telephone: +31 71 3322 388
E-mail: info@immunetune.com
